Comparative Pharmacology
Head-to-head clinical analysis: AXIRON versus FORTESTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXIRON versus FORTESTA.
AXIRON vs FORTESTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
One or two pump actuations (30 mg per actuation) applied to the axilla once daily; dose range 30-90 mg daily.
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
None Documented
None Documented
The terminal elimination half-life of testosterone is approximately 10-100 minutes after intravenous injection, but for Axiron (testosterone topical solution), the apparent half-life is about 1-2 hours due to continued absorption from the skin and distribution/elimination. Clinically, steady state is achieved after about 2 weeks of daily application.
Terminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (about 90%) and about 6% in feces via bile. Approximately 90% of a dose is excreted in urine, with the remainder in feces.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Category C
Category C
Androgen
Androgen